Significance of smoking status regarding outcomes after radical prostatectomy.
We aimed to investigate significance of smoking regarding pathologic and biochemical outcomes following radical prostatectomy (RP). We reviewed data of 1,165 patients who underwent RP without any neoadjuvant or adjuvant therapy at our institution. Patients were categorized into two groups for our analysis: smoking (current smoker at admission for surgery) and nonsmoking (never smoked or former smokers) group. Association of smoking status with adverse pathologic features and biochemical recurrence-free survival were analyzed according to patients' body mass index (BMI) as well as in total patients. In multivariate analyses, smoking was not found to be significantly associated with various adverse pathologic features and biochemical recurrence-free survival among total patients (all P > 0.05). However, when only the patients with BMI ≥ 25 kg/m(2) were analyzed, smoking at RP was observed to be an independent preoperative predictor of high (≥ 8) pathologic Gleason score (P = 0.025) and biochemical recurrence-free survival (P = 0.016) in multivariate analyses. Although smoking was not observed to be significantly associated with worse pathologic and biochemical outcome among overall patients who underwent RP, smoking was found to be a significant preoperative predictor of more aggressive disease and worse biochemical outcome among those with relatively higher BMI.